Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.

J&J beat expectations this week to launch the Q3 earnings season; a study about children treated with bluebird bio’s Skysona ...

Q3 2024 Earnings Call Transcript October 15, 2024 Johnson & Johnson beats earnings expectations. Reported EPS is $2.42, ...

Stelara is one of the most successful Crohn’s therapies, generating $10.8bn last year, Lilly hopes to introduce Omvoh as its ...

The drug is approved for multiple inflammatory conditions and is expected to launch in the first half of 2025.

On Tuesday, Johnson & Johnson (NYSE: JNJ) posted better-than-expected third quarter sales and adjusted profit. Fueled by strong results, Johnson & Johnson raised its full year profit and sales ...

The Food and Drug Administration (FDA) has approved Imuldosa ™ (ustekinumab-srlf), a biosimilar to Stelara ® (ustekinumab), for the treatment of various chronic inflammatory diseases. Imuldosa, ...

Biosimilar competition is expected in early January for the company’s second highest-selling drug, putting greater focus on newer products' market trajectory.

Johnson & Johnson's immunology superstar Stelara and oncology blockbuster Darzalex have long been among the company's top ...

At 52 weeks of follow-up, more patients on Eli Lilly’s monoclonal antibody Omvoh demonstrated histologic response, suggesting ...

Imuldosa is used for the treatment of patients with autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ...

Johnson & Johnson raised its 2024 profit and sales forecasts on Tuesday after reporting strong sales of oncology drugs and ...